Last reviewed · How we verify
β-1,3/1,6-D-glucan
β-1,3/1,6-D-glucan activates innate immune cells by binding to pattern recognition receptors, enhancing immune response and antimicrobial activity.
β-1,3/1,6-D-glucan activates innate immune cells by binding to pattern recognition receptors, enhancing immune response and antimicrobial activity. Used for Immune support and enhancement, Adjunctive therapy in infections.
At a glance
| Generic name | β-1,3/1,6-D-glucan |
|---|---|
| Also known as | Imurril capsules 100mg |
| Sponsor | Al-Azhar University |
| Drug class | Immunomodulator; biological response modifier |
| Target | Dectin-1 (β-glucan receptor); Complement receptor 3 (CR3) |
| Modality | Small molecule |
| Therapeutic area | Immunology; Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
β-glucans are polysaccharides derived from fungal cell walls that stimulate macrophages, neutrophils, and natural killer cells through Dectin-1 and complement receptor 3 binding. This activation enhances phagocytosis, cytokine production, and antimicrobial defense mechanisms. The compound is used as an immunomodulatory agent to support immune function and potentially improve outcomes in infections and certain disease states.
Approved indications
- Immune support and enhancement
- Adjunctive therapy in infections
Common side effects
- Mild gastrointestinal disturbance
- Fever or chills
- Allergic reactions
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- β-1,3/1,6-D-glucan CI brief — competitive landscape report
- β-1,3/1,6-D-glucan updates RSS · CI watch RSS
- Al-Azhar University portfolio CI